1-20 of 39
Monica Kwari
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy

Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Guilin Tang, Fadi G. Haddad, Nitin Jain, Ghayas C. Issa, Tapan M. Kadia, Naval Daver, Alessandra Ferrajoli, Monica Kwari, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Patrice Eric Nasnas, Naveen Pemmaraju, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 1500.
https://doi.org/10.1182/blood-2023-181379
Published: 2023
Journal Articles

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia

Nicholas Short, Courtney D. DiNardo, Naval Daver, Walid Macaron, Musa Yilmaz, Gautam Borthakur, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Ghayas C. Issa, Koji Sasaki, Philip A. Thompson, Jan A. Burger, Abhishek Maiti, Yesid Alvarado, Monica Kwari, Ricardo Delumpa, Jennifer Thankachan, Ejiroghene Mayor, Christopher Loiselle, Anna Milton, Glenda Banks, Tapan M. Kadia, Marina Konopleva, Hagop Kantarjian, Farhad Ravandi
Journal: Blood
Blood (2022) 140 (Supplement 1): 2007–2009.
https://doi.org/10.1182/blood-2022-157210
Published: 2022
Journal Articles

Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study

Walid Macaron, Hagop Kantarjian, Nicholas Short, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Tapan M. Kadia, Naval Daver, Kelly S. Chien, Yesid Alvarado, Guillermo Garcia-Manero, Ghayas C. Issa, Fadi Haddad, Monica Kwari, Ricardo Delumpa, Ejiroghene Mayor, Wuliamatu Deen, Jennifer Thankachan, Christopher Loiselle, Juan Rivera, Anna Milton, Lourdes Waller, Glenda Banks, Rebecca Garris, Marina Konopleva, Farhad Ravandi, Elias Jabbour
Journal: Blood
Blood (2022) 140 (Supplement 1): 8973–8975.
https://doi.org/10.1182/blood-2022-157323
Published: 2022
Journal Articles

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

Nicholas Short, Elias Jabbour, Farhad Ravandi, Musa Yilmaz, Tapan M. Kadia, Philip A. Thompson, Xuelin Huang, Marina Konopleva, Alessandra Ferrajoli, Nitin Jain, Koji Sasaki, Walid Macaron, Yesid Alvarado, Gautam Borthakur, Courtney D. DiNardo, Maro Ohanian, Steven M. Kornblau, Min Zhao, Monica Kwari, Jennifer Thankachan, Christopher Loiselle, Ricardo Delumpa, Rebecca Garris, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 8966–8968.
https://doi.org/10.1182/blood-2022-157358
Published: 2022
Journal Articles

Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results

Patrice Nasnas, Elias Jabbour, Nicholas Short, Koji Sasaki, Farhad Ravandi, Nitin Jain, Naval Daver, Naveen Pemmaraju, Musa Yilmaz, Tapan M. Kadia, Rebecca Garris, Guillermo Garcia-Manero, Courtney D. DiNardo, Marina Konopleva, William G. Wierda, Monica Kwari, Christopher Loiselle, Anna Milton, Juan Rivera, Glenda Banks, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 3250–3252.
https://doi.org/10.1182/blood-2022-167761
Published: 2022
Journal Articles

A Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Updated Results and Predictors for Outcomes

Patrice Nasnas, Elias Jabbour, Nicholas Short, Farhad Ravandi, Xuelin Huang, Nitin Jain, Tapan M. Kadia, Yesid Alvarado, Jan A. Burger, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Marina Konopleva, Guillermo Garcia-Manero, William G. Wierda, Jovitta Jacob, Wuliamatu Deen, Monica Kwari, Christopher Loiselle, Edith Roy, Anna Milton, Juan Rivera, Rebecca Garris, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 11679–11682.
https://doi.org/10.1182/blood-2022-168052
Published: 2022
Journal Articles

Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study

Nicholas Short, Hagop Kantarjian, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Tapan M. Kadia, Naval Daver, Kelly S. Chien, Yesid Alvarado, Guillermo Garcia-Manero, Ghayas C. Issa, Walid Macaron, Fadi Haddad, Monica Kwari, Ricardo Delumpa, Ejiroghene Mayor, Wuliamatu Deen, Jennifer Thankachan, Christopher Loiselle, Juan Rivera, Anna Milton, Lourdes Waller, Glenda Banks, Rebecca Garris, Marina Konopleva, Farhad Ravandi, Elias Jabbour
Journal: Blood
Blood (2022) 140 (Supplement 1): 513–515.
https://doi.org/10.1182/blood-2022-157775
Published: 2022
Journal Articles

Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia

Jayastu Senapati, Nicholas Short, Nitin Jain, Farhad Ravandi, Tharakeswara K. Bathala, Aram Bidikian, Fadi Haddad, Patrice Nasnas, Naval Daver, Tapan M. Kadia, Rebecca Garris, Monica Kwari, Hagop Kantarjian, Elias Jabbour
Journal: Blood
Blood (2022) 140 (Supplement 1): 3182–3184.
https://doi.org/10.1182/blood-2022-170931
Published: 2022
Journal Articles

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Nicholas J. Short, Hagop Kantarjian, Farhad Ravandi, Xuelin Huang, Nitin Jain, Tapan M. Kadia, Joseph D. Khoury, Jeffrey L. Jorgensen, Sa A Wang, Yesid Alvarado, Jan A. Burger, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Marina Konopleva, Naveen Pemmaraju, Guillermo Garcia-Manero, William G. Wierda, Steven M. Kornblau, Jovitta Jacob, Monica Kwari, Caitlin R. Rausch, Christopher Loiselle, Anna Milton, Juan Rivera, Rebecca Garris, Susan M. O'Brien, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 3400.
https://doi.org/10.1182/blood-2021-154074
Published: 2021
Journal Articles

A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation

Sai Prasad Desikan, Farhad Ravandi, Naveen Pemmaraju, Marina Konopleva, Sanam Loghavi, Gautam Borthakur, Elias J. Jabbour, Naval Daver, Nitin Jain, Kelly S. Chien, Abhishek Maiti, Guillermo Montalban-Bravo, Tapan M. Kadia, Monica Kwari, Hagop Kantarjian, Nicholas J. Short
Journal: Blood
Blood (2021) 138 (Supplement 1): 4436.
https://doi.org/10.1182/blood-2021-151707
Published: 2021
Journal Articles

Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Philip A. Thompson, MB, MS, Yesid Alvarado, MD, Nitin Jain, MD, Musa Yilmaz, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Steven M. Kornblau, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Heather M Schroeder, Monica Kwari, BSN, Shilpa Paul, PharmD, Benjamin Nwakanme, Christopher Loiselle, BS, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–11.
https://doi.org/10.1182/blood-2020-138565
Published: 2020
Journal Articles

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, C. Cameron Yin, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Koichi Takahashi, MD PhD, Bouthaina S. Dabaja, MD, Srdan Verstovsek, MD PhD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Caitlin R. Rausch, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Patrice Nasnas, MD, Rita Khouri, Monica Kwari, BSN, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–47.
https://doi.org/10.1182/blood-2020-143401
Published: 2020
Journal Articles

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Nitin Jain, MD, Tapan M. Kadia, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Yesid Alvarado, MD, Jan A. Burger, MD PhD, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Steven M. Kornblau, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Monica Kwari, BSN, Caitlin R. Rausch, PharmD, Christopher Loiselle, BS, Anna Milton, Juan Rivera, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–17.
https://doi.org/10.1182/blood-2020-138569
Published: 2020
Journal Articles

Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2 -Mutated Myelodysplastic Syndromes (MDS)

Guillaume Richard-Carpentier, MD, Amy E. DeZern, MD, Koichi Takahashi, MD, Marina Y Konopleva, MD PhD, Sanam Loghavi, MD, Lucia Masarova, MD, Yesid Alvarado, MD, Farhad Ravandi, MD, Guillermo Montalban Bravo, MD, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Ricardo Delumpa, BSN, Monica Kwari, BSN, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD, Gail J. Roboz, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Courtney D. DiNardo, MD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 678.
https://doi.org/10.1182/blood-2019-130501
Published: 2019
Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Michael E. Rytting, MD, Nitin Jain, MD, Marina Y Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Jorge E. Cortes, MD, Zeev E. Estrov, MD, Koichi Takahashi, MD, Christopher Loiselle, BS, Corabelle Encarnacion, RDC, Meagan Rostykus, RN, Rita Khouri, Patrice Nasnas, MD, Jovitta Jacob, RN, Monica Kwari, BSN, Rebecca Garris, MSc, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3806.
https://doi.org/10.1182/blood-2019-129018
Published: 2019
Journal Articles

Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Guillaume Richard-Carpentier, MD, Hagop M. Kantarjian, MD, Nicholas J. Short, MD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Heather M Schroeder, Guillermo Garcia-Manero, MD, Guillermo Montalban Bravo, MD, Jorge E. Cortes, MD, Monica Kwari, BSN, Christopher Loiselle, BS, Rebecca Garris, MSc, Nicole Volter, RDC, Nitin Jain, MD, Marina Y Konopleva, MD PhD, Koichi Takahashi, MD, Koji Sasaki, MD, William G. Wierda, MD PhD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3807.
https://doi.org/10.1182/blood-2019-129657
Published: 2019
Journal Articles

Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Guillaume Richard-Carpentier, MD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Keyur P. Patel, MBBS, PhD, Kathryn G. Roberts, PhD, Zhaohui Gu, PhD, Farhad Ravandi, MD, Nitin Jain, MD, Nicholas J. Short, MD, Guillermo Garcia-Manero, MD, Heather M Schroeder, Monica Kwari, BSN, Rebecca Garris, MSc, Rita Khouri, Mike Jones, RDC, Christopher Loiselle, BS, Jorge E. Cortes, MD, Koji Sasaki, MD, Ghayas C. Issa, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Srdan Verstovsek, MD PhD, Naval G. Daver, MD, Charles G. Mullighan, MBBS, MD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2577.
https://doi.org/10.1182/blood-2019-129884
Published: 2019
Journal Articles

Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Kelly S. Chien, MD, Christopher B. Benton, MD, Ayalew Tefferi, MD, José Rodríguez, MD PhD, Farhad Ravandi, MD, Naval G. Daver, MD, Elias J. Jabbour, MD, Nitin Jain, MD, Yesid Alvarado, MD, Monica Kwari, BSN, Sherry A. Pierce, BSN, BA, Abhishek Maiti, MBBS, Marisa J Hornbaker, BS, Margarida Almeida Santos, PhD, Sara Martinez, MD, Mariano Siguero, Darci Zblewski, APRN, C-NP, Aref Al-Kali, MD, William J. Hogan, MBBCh, Hagop M. Kantarjian, MD, Animesh Pardanani, MBBS, PhD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2722.
https://doi.org/10.1182/blood-2018-99-115673
Published: 2018
Journal Articles

Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study

Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Naval G. Daver, MD, Gautam Borthakur, MD, Nitin Jain, MD, Jane Waukau, RN, BSN, Monica Kwari, RN, BSN, Barry Douglas Anderson, MD PhD, Kenzo Iizuka, Cheng Jin, MD PhD, Chun Zhang, MD, Farhad Ravandi, MD, William Plunkett, PhD
Journal: Blood
Blood (2016) 128 (22): 2822.
https://doi.org/10.1182/blood.V128.22.2822.2822
Published: 2016
Journal Articles

Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia

Hagop Kantarjian, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, Courtney DiNardo, MD, Naval Daver, MD, Gautam Borthakur, MD, Nitin Jain, MD, Jane Waukau, RN, BSN, Monica Kwari, RN, BSN, Barry Douglas Anderson, MD PhD, Kenzo Iizuka, Cheng Jin, MD PhD, William Plunkett, PhD
Journal: Blood
Blood (2015) 126 (23): 3804.
https://doi.org/10.1182/blood.V126.23.3804.3804
Published: 2015